Emerging Growth Patterns Driving Expansion in the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market

Exploring the future landscape of molecular diagnostics reveals a promising trajectory for next-generation sequencing (NGS)-based technologies. As innovations continue to reshape healthcare diagnostics, the NGS-based molecular diagnostics market is positioned for substantial growth, driven by technological advancements and increasing demand for personalized medicine. Let's delve into the market's size, key players, emerging trends, and segmentation to understand its evolving dynamics.

Projected Market Size and Growth of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market
The NGS-based molecular diagnostics market is anticipated to experience significant expansion, reaching a valuation of $3.23 billion by 2030. This represents a compound annual growth rate (CAGR) of 7.3% during the forecast period. The market's upward momentum is fueled by several factors, including the integration of artificial intelligence (AI) and machine learning into diagnostic processes, broader adoption of cloud-based genomic platforms, advancements in portable and point-of-care sequencing devices, a surge in personalized medicine applications, and strategic collaborations between diagnostics and biotech firms. Additionally, key trends shaping the market include AI-assisted diagnostics, enhanced cloud genomic analysis tools, portable sequencing innovations, incorporation of bioinformatics workflows, and rapid detection of disease markers.

Download a free sample of the next-generation sequencing (ngs)-based molecular diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Key Factors Contributing to Market Expansion
One major driver behind the growth of the NGS-based molecular diagnostics market is the increasing incorporation of AI and machine learning techniques. These technologies allow for improved accuracy and speed in interpreting complex genomic data, making diagnostics more precise and efficient.
Another significant factor is the development of cloud-based genomic platforms which enable easier data sharing and analysis across institutions and researchers. This fosters collaboration and accelerates breakthroughs in molecular diagnostics, enhancing the accessibility and scalability of NGS applications.

Top Companies Leading the NGS-Based Molecular Diagnostics Sector
The competitive landscape of this market features several prominent players, including Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., and TATAA Biocenter AB.
In a notable recent development, in January 2023, Qiagen NV, based in Germany, acquired Verogen Inc., a US company specializing in forensic genomics NGS solutions. This acquisition strengthens Qiagen's position in human identification and forensic genomic applications while expanding its reach into public sector and private sector markets including genetic genealogy.

View the full next-generation sequencing (ngs)-based molecular diagnostics market report:
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-ngs-based-molecular-diagnostics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Emerging Trends Shaping the Future of NGS Molecular Diagnostics
Industry leaders are increasingly focusing on the development of advanced NGS-based panels designed to improve the accuracy, accessibility, and efficiency of genetic testing. These panels target specific genes or genomic regions, enabling simultaneous analysis that facilitates quick and precise molecular diagnostics.
For example, in April 2024, Pillar Biosciences, a US diagnostics firm, received FDA clearance for its oncoReveal CDx pan-cancer solid tumor IVD kit. This panel analyzes 22 clinically important genes in one multiplex reaction, compatible with Illumina's MiSeq Dx system. It offers a rapid sample-to-report turnaround of about 48 hours and can process up to 46 clinical samples per run. The oncoReveal CDx supports companion diagnostic claims for KRAS (used in EGFR-targeted colorectal cancer therapies) and EGFR (for tyrosine kinase inhibitor therapy in non-small-cell lung cancer), enabling more efficient detection of actionable genomic variations to guide clinical decisions.

Breakdown of Core Segments Within the Global NGS Molecular Diagnostics Market
The global market for NGS-based molecular diagnostics is categorized into several principal segments:
1) By Type: Instruments, Reagents and Consumables, Software and Services, Panels and Assays, Sample Preparation Kits
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Testing, Other Applications
3) By End User: Research Centers and Academic Institutions, Hospitals and Clinical Laboratories, Other End Users

Detailed subcategories include:
- Instruments such as benchtop sequencers, high-throughput sequencers, portable or handheld sequencers, clinical sequencers, automated library preparation systems, and bioinformatics hardware.
- Reagents and consumables comprising sequencing kits, library preparation reagents, target enrichment products, amplification reagents, sequencing flow cells and chips, DNA/RNA extraction reagents, and quality control substances.
- Software and services including data analysis programs, bioinformatics pipelines, cloud genomic platforms, clinical interpretation tools, data management services, customized bioinformatics, and genomic databases.
- Panels and assays covering oncology, infectious disease, carrier screening, reproductive health, rare disease/genetic disorder, pharmacogenomics, and whole-exome or whole-genome assays.
- Sample preparation kits for DNA/RNA extraction, library preparation, target enrichment, amplification and cleanup, single-cell preparation, and kits specialized for low-input or degraded samples.

This detailed segmentation highlights the comprehensive nature of the NGS-based molecular diagnostics market and reflects the myriad applications and technologies driving its growth.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.